A
continuing clinical study in non-urban Uganda, begun in 2011, means that many
individuals infected with HIV/AIDS would take antiretroviral drugs whenever
they were really offered to them even well before they developed indications
direct from disorder.
Led
by doctors for the University of California, San Francisco (UCSF), the San
Francisco General Hospital and Trauma Center (SFGH) and Makerere University
School of Medicine in Kampala, Uganda, the research is the first to deal with
such attitudes among African affected individuals who are in the early phases
of the disease, but not yet sick.
Now,
mounting fact means that giving antiretroviral therapy to individuals long
before they actually get sick may be a direct advantage to both them and
society by keeping the person strong, and by cutting down on the transmission
of HIV present in communities.
However,
experts have known little about patients' attitudes to taking antiretroviral
therapy back in the early stages of HIV disease. "Given that we now have
millions of people in Africa using antiretroviral drugs and millions more
requiring them, there are remarkably little facts on patients' behavior
globally toward the therapy itself," said Moses Kamya, a professor and
chair of the Department of Medicine at Makerere University.
"There
arised very high interest among the people eligible for this research in using
antiretrovirals," said Vivek Jain, MD, MAS, assistant professor of
medicine in the UCSF Division of HIV/AIDS at SFGH.
In
the survey, 188 affected individuals with HIV were enrolled and supplied
antiretroviral drugs. All skilled a high CD4 T cell count the classic measure
of the immune system's robustness and a signal of getting in the early phases of
illness, before a repudiate to Acquired Immune Deficiency Syndrome.
No comments:
Post a Comment